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Purpose of study
The SLCO1A2 influx transporter is located in the liver,
intestine, brain and kidneys. A number of functional sin-
gle nucleotide polymorphisms (SNPs) have been reported
in the SLCO1A2 gene (including 516A>C and 38 T>C).
The aim of this study was to determine if LPV is a substrate
for SLCO1A2 in vitro and to assess whether these SNPs
impact upon LPV plasma concentrations.
Methods
SLCO1A2 was cloned (with Kozak sequence) into pBlue-
scriptII-KSM, flanked by the 5' and 3' X. laevis β-globin
UTR and cRNA was generated by in vitro transcription.
SLCO1A2 or water-injected oocytes were incubated with
estrone-3-sulphate ([3H]-E3S; 1 μM; 0.33 μCi/ml; posi-
tive control) or [3H]-LPV (1 μM, 0.33 μCi/ml). Statistical
analyses were performed on log transformed data by a
paired t-test (n = 4 experiments with at least six replicates).
Archived plasma samples were available from patients (n
= 400) who had previously undergone therapeutic drug
monitoring (TDM). LPV peak (2–6 hr) and trough (10–14
hr) concentrations were available. The following exclu-
sion criteria were applied; age <18 years, pregnancy,
deranged LFTs and the use of rifamycins, anticonvulsants,
acid-reducing agents or NNRTIs. SLCO1A2 516A>C and
38T>C were genotyped using real-time allelic discrimina-
tion and statistical analysis was performed by Mann Whit-
ney.
Summary of results
SLCO1A2-injected oocytes had significantly higher E3S
accumulation compared to water-injected oocytes (0.51 ±
0.17 vs. 0.16 ± 0.04 (pmol/oocyte), p < 0.05) and signifi-
cantly higher accumulation of LPV (4.30 ± 0.72 vs. 2.14 ±
0.43, p < 0.05). The allele frequencies of 516C and 38C
were 2.5% and 5.8%, respectively. The median (range)
Ctrough for 516 AA, AC and CC were 5,170 (818–22,432)
4,859 (2,008–14,273) and 5,609 (1,174–8,396) ng/mL,
respectively (p > 0.05). The median (range) Ctrough for
38 TT, TC and CC were 5,023 (818–22,432), 5,778 (833–
21,945) and 3,899 (2,380–6,815) ng/mL, respectively (p
> 0.05). Also, no association with peak concentrations
was observed.
Conclusion
These data indicate that LPV is a substrate for SLCO1A2.
However, SLCO1A2 516A>C and 38T>C did not influence
plasma concentrations of LPV and does not therefore
appear to be a major determinant of intersubject variabil-
ity. These data must be interpreted with caution due to the
limitations associated with a TDM cohort (i.e. selection
bias and lack of ethnicity data). As with all pharmacoge-
netic data, the findings warrant confirmation in other
cohorts.
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